ZWZhiguo Wang

Zhiguo Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhiguo Wang has a total of 169 co-authors. Here are the top co-authors by number of shared publications:

  • Wei Wang

    Chinese Acad Med Sci, Beijing Hosp, Inst Geriatr Med, Natl Ctr Clin Labs,Natl Ctr Gerontol, Beijing, Peoples R China

    28 shared publications
  • Falin He

    Chinese Acad Med Sci, Beijing Hosp, Inst Geriatr Med, Natl Ctr Clin Labs,Natl Ctr Gerontol, Beijing, Peoples R China

    21 shared publications
  • Kun Zhong

    National Center for Clinical Laboratories, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology , Beijing , P.R. China

    19 shared publications
  • Shuai Yuan

    National Center for Clinical Laboratories, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology , Beijing , P.R. China

    15 shared publications
  • Haijian Zhao

    National Center for Clinical Laboratories/Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, National Center of Gerontology, Dongcheng District, Beijing, P.R. China

    14 shared publications
  • Yuxuan Du

    Chinese Acad Med Sci, Beijing Hosp, Inst Geriatr Med, Natl Ctr Clin Labs,Natl Ctr Gerontol, Beijing, Peoples R China

    9 shared publications

Latest Publications

  • Results of a Pilot External Quality Assessment Scheme for Genetic Testing of Newborns with Spinal Muscular Atrophy

    by Wei Wang, Liping Wu, Yufan Hui, Yuxuan Du, Jiangtao Yang, Panpan Jiang, Maosheng Gu, Hongqin He, Li Qiu, Zhiqiang Zhang, et al.

    Background: This study aims to evaluate the ability of laboratories to perform spinal muscular atrophy (SMA) genetic testing in newborns based on dried blood spot (DBS) samples, and to provide reference data and advance preparation for establishing the pilot external quality assessment (EQA) scheme for SMA genetic testing of newborns in China. Methods: The pilot EQA scheme contents and evaluation principles of this project were designed by National Center for Clinical Laboratories (NCCL), National Health Commission. Two surveys were carried out in 2022, and 5 batches of blood spots were submitted to the participating laboratory each time. All participating laboratories conducted testing upon receiving samples, and test results were submitted to NCCL within the specified date. Results: The return rates were 75.0% (21/28) and 95.2% (20/21) in the first and second surveys, respectively. The total return rate of the two examinations was 83.7% (41/49). Nineteen laboratories (19/21, 90.5%) had a full score passing on the first survey, while in the second survey twenty laboratories (20/20, 100%) scored full. Conclusions: This pilot EQA survey provides a preliminary understanding of the capability of SMA genetic testing for newborns across laboratories in China. A few laboratories had technical or operational problems in testing. It is, therefore, of importance to strengthen laboratory management and to improve testing capacity for the establishment of a national EQA scheme for newborn SMA genetic testing.

  • Analysis of Imprecision for Internal Quality Control of Newborn Screening by Tandem Mass Spectrometry in China, 2015 - 2021

    by Wei Wang, Yuxuan Du, Falin He, Na Dong, Zhiguo Wang

    Background: This study aimed to assess the performance of the newborn screening laboratories in China through retrospective analysis of the coefficient of variation (CV) of the internal quality control (IQC) data in the national tandem mass spectrometry screening for inherited metabolic disorders in newborns. Methods: From 2015 to 2021, the IQC data of amino acid and acylcarnitine test were collected twice each year. CVmonthly in-control was calculated by excluding outliers for the current month and its discrete distribution and changes in trend were comprehensively evaluated for both normal and high concentration levels. The proportion of laboratories meeting both 1/3 and 1/4 quality criteria of the total error allowable (TEa), based on the CVmonthly in-control for each testing item, was calculated. Results: The analysis of CVmonthly in-control for the two concentration levels for the amino acids and acylcarnitine parameters showed that CVmonthly in-control for the normal concentration levels were more discrete before 2018, while CVmonthly in-control for the high concentration levels were less discrete than the normal concentration levels, but there were relatively more outliers. More than 80% of laboratories were able to meet the 1/3 TEa standard for each test at the high concentration level, while the pass rate for the 1/4 TEa standard was significantly lower than 80% Conclusions: According to the current status of testing in China, it is recommended to use 1/3TEa as the imprecision level standard; for laboratories with relatively high precision, the 1/4TEa standard can be used.

  • Open Access

    Evaluation laboratory prenatal screening performance based on biological variation of risk assessment in second trimester in China

    by Falin He, Kun Zhong, Shuai Yuan, Yuxuan Du, Wei Wang, Zhiguo Wang

    Objectives: This study intends to evaluate prenatal screening risk assessment performance based on biological variation to help clinical laboratories realize their own screening performance and set the appropriate performance specifications for prenatal screening risk assessment in China. Methods: Fifteen samples with detailed clinical information were distributed to participants and the prenatal screening Down syndrome risk assessment of each sample were submitted. Three levels of performance specification (optimum, desirable, minimum) derived from biological variation were used to evaluate laboratory prenatal screening risk assessment performance. Results: A total of 797 laboratories participated in the survey project. There are 216 laboratories using serological double-marker test and 581 laboratories using serological triple-marker test. For each screening protocol, more than 92.00% laboratories meet minimum performance specifications, more than 84.00% laboratories meet desirable performance specifications, and only about 62.50%laboratories meet optimum performance specifications. The Feltz and Miller test indicated that there were no significant statistical differences in the RCV for double-marker screening in 5 platforms and triple-marker screening in 6 platforms. Conclusions: The risk assessment of prenatal screening in the second trimester in China can be improved further. It is appropriate to choose desirable performance specifications for external quality assurance organizations to evaluate the risk assessment performance.


  • A New Practical Tool for Assessing the Analytical Performance and Designing Risk-Based Statistical Quality Control Procedures in Laboratories

    by Jiali Liu, Yongjun Guo, Wei Wang, Fengfeng Kang, Xiangyi Liu, Zhiguo Wang

    Background: We developed a new practical tool and applied it to assess the performance of 14 biochemical assays and designed risk-based statistical quality control (SQC) procedures.Methods: Two graphs were combined to develop the new tool. Data points of assays were plotted on the tool to de-termine their sigma performance and the risk-based SQC procedures. The quality goal index (QGI) was also cal-culated for quality improvement.Results: Among 14 assays, total bilirubin, direct bilirubin, alanine aminotransferase, creatine kinase, and gamma-glutamyl transferase achieved 6-sigma performance, the recommended SQC procedure was 13s rule (n = 2) with a run size of 1,000 patient samples. Triglycerides was 5-sigma quality and could be controlled with 13s/22s/R4s multi -rule procedure (n = 2) with a run size of 450. Uric acid, creatinine, total cholesterol, and aspartate aminotransfe-rase obtained 4-sigma quality and could be controlled using 13s/22s/R4s/41s multi-rule procedure (n = 4) with run size of 200. The performance for urea, alkaline phosphatase, amylase, and lactate dehydrogenase was 3-sigma and 13s/22s/R4s/41s/6X multi-rule procedure (n = 6) with run size of 45 was recommended. The QGI for assays with sig-ma quality below 6.0 were all less than 0.8. Conclusions: The developed tool can be used to simplify laboratory practices in assessing analytical performance and designing SQC procedures.

  • Open Access

    Reference Standards for Newborn Screening of Metabolic Disorders by Tandem Mass Spectrometry: A Nationwide Study on Millions of Chinese Neonatal Populations

    by Falin He, Rulai Yang, Xinwen Huang, Yaping Tian, Xiaofang Pei, Mary Kathryn Bohn, Lin Zou, Yan Wang, Haibo Li, Ting Wang, et al.

    Introduction: The major clinical problem presently confronting the Chinese newborn screening (NBS) programs by tandem mass spectrometry (MS/MS) is the lack of comprehensive reference intervals (RIs) for disease biomarkers. To close this gap, the Chinese National Center for Clinical Laboratories (NCCL) launched a nationwide study to investigate the dynamic pattern of 35 MS/MS NBS biomarkers and establish accurate and robust RIs.Methods: Blood spot samples from 4,714,089 Chinese neonates were tested in participating centers/laboratories and used for study analysis. MS/MS NBS biomarker trends were visually assessed by their concentrations over age. Specific partitions were determined arbitrarily by each day and sex or by the statistical method of Harris and Boyd. RIs, corresponding to the 2.5th and 97.5th percentiles, as well as the 1th, 25th, 75th and 99th percentiles were calculated for each reference partition using a non-parametric rank approach.Results: Most MS/MS NBS biomarkers fluctuated during the first week of life, followed by a relatively stable concentration. Age and sex-specific RIs were established and presented an improved specificity over the RIs used in participating centers/laboratories. Females demonstrated higher 2.5th and 97.5th percentiles in all amino acids except arginine and ornithine than males, whereas males showed higher 2.5th and 97.5th percentiles in most acylcarnitines.Conclusion: The present study determined the dynamic trends of 35 MS/MS biomarkers and established age and sex-specific RIs, valuably contributing to the current literature and timely evaluation of neonatal health and disease.


  • Open Access

    National Program for External Quality Assessment of Chinese Newborn Screening Laboratories

    by Yuxuan Du, Wei Wang, Jiali Liu, Zhixin Zhang, Zhen Zhao, Falin He, Shuai Yuan, Zhiguo Wang

    Objectives: To analyze the coefficient of variation (CV) of external quality assessment (EQA) in Chinese newborn screening (NBS) laboratories. Method: EQA’s robust CV was analyzed by the Clinet-EQA evaluation system. Results: Participating laboratories of the EQA program increased annually. There was more than a 11-fold increase in phenylalanine (Phe) and thyroid stimulating hormone (TSH). It has shown a declining robust CV, which has tended to level off in recent years. The interquartile range (IQR) of Phe and TSH’s robust CV has decreased from 15.5% to 1.5% and from 22.8% to 1.8%, respectively. Compared to bacterial inhibition assay (BIA), the robust CV of Phe has been shown to be relatively reduced in the fluorescence assay and quantitative enzymatic assay (QEA). The robust CV by ELISA was relatively unstable compared to DELFIA and FEIA. In addition, the robust CVs of glucose-6-phosphate dehydrogenase (G6PD) and 17-alpha-hydroxy progesterone (17-OHP) by Genetic Screening Processor (GSP) were lower than other systems. The median of robust CV by non-derivatized MS/MS (Fenghua) in Phe and free carnitine were around 2.2–4.7% and 2.6–5.2%. Conclusion: Neonatal screening has developed rapidly in China and the majority of participant laboratories had satisfactory performance for the quantitative results.


  • Open Access

    National survey on delta checks in clinical laboratories in China

    by Shukang He, Fengfeng Kang, Wei Wang, Bingquan Chen, Zhiguo Wang

    Background This study aimed to understand the status quo of delta checks in Chinese clinical laboratories through a nationwide online survey. Methods The survey was divided into two parts. The first part was a general situation survey in which clinical laboratories had to provide information about the laboratories, including delta checks used. In the second part, clinical laboratories were asked to record the delta check alerts generated in their laboratories from June 1st, 2019 to June 30th, 2019. Results The most frequently used analytes in delta checks were potassium (K), glucose (Glu), creatinine (Cre) for clinical chemistry and hemoglobin (Hgb), platelet (PLT) count and white blood cell (WBC) count for clinical hematology. The median maximum time interval between specimens for all analytes was 5 days. The most commonly used delta check calculation modes in Chinese clinical laboratories were percentage change and absolute change. K and Hgb were the analytes most involved in clinical chemistry and clinical hematology delta check alerts. The most common causes of delta check alerts were that the patients had received treatment, which was followed by the change in the patient's physiological state and interference from hemolysis, lipemia and icterus. The two most common outcomes of delta check alerts were 'no problems found, standard report issued' and 'no problems found, report issued with comment'. Conclusions This study was the first nationwide survey of delta checks in China, the results of which help us to understand the current situation of delta checks in Chinese clinical laboratories.


  • Chinese newborn screening for the incidence of G6PD deficiency and variant of G6PD gene from 2013 to 2017

    by Zhidai Liu, Chaowen Yu, Qingge Li, Ren Cai, Yiping Qu, Weipeng Wang, Jie Wang, Jinwen Feng, Wenbin Zhu, Mingcai Ou, et al.

    Glucose‐6‐phosphate dehydrogenase (G6PD) deficiency is one of the most common X‐linked enzymopathies caused by G6PD gene variant. We aimed to provide the characteristics of G6PD deficiency and G6PD gene variant distribution in a large Chinese newborn screening (NBS) population. We investigated the prevalence of G6PD in China from 2013 to 2017. Then we examined G6PD activity and G6PD gene in representative Chinese birth cohort to explore the distribution of G6PD gene variant in 2016. We then performed multicolour melting curve analysis (MMCA) to classify G6PD gene variants in 10,357 neonates with activity‐confirmed G6PD deficiency, and DNA Sanger sequencing for G6PD coding exons if hot site variants were not found. The screened population, organizations and provinces of G6PD deficiency were increased from 2013 to 2017 in China. The top 5 frequency of G6PD gene variants were c.1376G>T, c.1388G>A, c.95A>G, c.1024C>T, and c.871G>A and varied in different provinces, with regional and ethnic features, and 4 pathogenic variant sites (c.152C>T, c.290A>T, c.697G>C, and c.1285A>G) were firstly reported. G6PD deficiency mainly occurs in South China, and the frequency of G6PD gene variant varies in different regions and ethnicities.


  • External Quality Assessment Program for Newborn Screening of Acylcarnitine in China, 2018

    by Falin He, Wei Wang, Shuai Yuan, Yuxuan Du, Kun Zhong, Zhiguo Wang

    Background: The aim of this study was to analyze the 2018 external quality assessment (EQA) results of newborn screening by MS/MS of acylcarnitine by Chinese National Center for Clinical Laboratories and to determine the performance of clinical laboratories. Methods: Five dried blood spots were distributed to participants every round. Satisfactory performance was defined as scores more than 80 of acceptable results within the evaluation criterion. The robust coefficient of variability (RCV) of each sample was calculated by measurement systems. The chi-square (chi(2)) test was used to compare the correct recognition rates. Results: EQA results were collected from 150 laboratories for 15 different acylcarnitines between C0 - C18. The overall acceptable rates of the qualitative results were between 81.21% and 96.67%, and the proportion of acceptable quantitative results were between 78.38% and 93.24%. There were significant differences in the rates of acceptable quantitative results among different items and between the four methods. Conclusions: Most of the participant laboratories had satisfactory performance for the quantitative results in this EQA scheme. But for qualitative assessment, a laboratory should re-evaluate and validate their reference intervals on a regular basis to improve the consistency of clinical assessment.


  • Analysis and evaluation of the external quality assessment results of quality indicators in laboratory medicine all over China from 2015 to 2018

    by Min Duan, Fengfeng Kang, Haijian Zhao, Wei Wang, Yuxuan Du, Falin He, Kun Zhong, Shuai Yuan, Bingquan Chen, Zhiguo Wang

    Background: This study aimed to comprehensively evaluate laboratory quality in China and explore factors affecting laboratory errors through analyzing the external quality assessment (EQA) results of quality indicators (QIs). Methods: According to model 3 (interpretive) of the proficiency testing scheme, the National Center for Clinical Laboratories of China (CNCCL) developed a questionnaire for 15 QIs. Clinical laboratories from different provinces of China participated in the EQA program of QIs annually and submitted data via an online reporting system named Clinet-EQA. The results of QIs were expressed in percentage and sigma value or minute. Three levels of quality specifications (QSs) were defined based on percentile values. Furthermore, the QIs were analyzed by disciplines, hospital scales and information construction levels of participant laboratories. Results: A total of 3450 laboratories nationwide continuously attended the EQA program and submitted complete data from 2015 to 2018. The performance of most QIs has improved year by year. QIs in post-analytical gained the best performance with sigma values that varied from 5.3σ to 6.0σ. The comparison of results among different disciplines showed significant differences for five QIs. More than half of QIs had statistical differences among different hospital scales measured by hospital grades and number of hospital beds. The performance of nine QIs were influenced by information construction levels of participant laboratories. Conclusions: The overall laboratory quality in China has improved since the initiation of EQA program for QIs, but the performance of some QIs was still unsatisfactory. Therefore, laboratories should make efforts for continuous quality improvement based on information provided by QSs.